[19 May 2011]
Products Affected - Description
Xylocaine 1% Preservative-Free Injection, APP
10 mg/mL 30 mL vial (NDC 63323-0492-30) - discontinued
10 mg/mL 5 mL vial (NDC 63323-0492-05) - discontinued
Reason for the Shortage
- Hospira’s lidocaine 1% injection presentations were on back order due to a supply interruption.
- APP states the shortage was due to increased demand for product. Also, APP is transitioning to new packaging with new NDC numbers for several Xylocaine products.
Estimated Resupply Dates
- APP has available Xylocaine 1% preservative-free 10 mg/mL injection 2 mL vials (NDC 63323-04-92-02) 5 mL (NDC 63323-0492-89) ampules, 5 mL vials (NDC 63323-0492-57), 30 mL single-dose vials (NDC 63323-0492-37), 30 mg sterile pack vials (NDC 63323-0492-31), and 2 mL (NDC 63323-0492-80) ampules.
- Hospira has available lidocaine 1% preservative-free injection 2 mL ampules (NDC 63323-0492-02). Lidocaine 1% preservative-free 30 mL single-dose vials (NDC 00409-4279-02), 30 mL sterile pack vials (NDC 00409-4270-01), and 5 mL ampules (NDC 00409-4713-02) are available. The company also has available Lidocaine 1% 5 mL Ansyr syringes (NDC 00409-9137-05) and 5 mL Lifeshield Abboject syringes (NDC 00409-4904-34).
May 19, 2011; May 12, 2011; April 20, 2011; March 10, 2011; March 8, 2011; February 11, 2011; January 25, 2011; January 6, 2011, University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins